Analyst calls Orphazyme's 300 percent value jump "strange and noteworthy"
Danish biotech company Orphazyme experienced a dramatic value increase on the US stock exchange on Thursday, with trading of the share suspended 20 times. Nordnet analyst Per Hansen calls the increase illogical.
BY RITZAU, TRANSLATED BY CATHERINE BRETT
On Thursday, Danish biotech company Orphazyme experienced a dramatic value jump on the US stock exchange.
In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.
The US retail chain has stopped selling its own private label hearing aids – and until the next generation comes along, other hearing companies selling products via Costco are enjoying the empty shelf space.